Bukwang Pharmaceutical Co., Ltd. (003000.KS)
KRW 4745.0
(-1.35%)
KRW 4745.0
(-1.35%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 442.46 Billion KRW | 10.36% |
| 2022 | 400.92 Billion KRW | 0.88% |
| 2021 | 397.41 Billion KRW | -0.89% |
| 2020 | 400.96 Billion KRW | 3.2% |
| 2019 | 388.53 Billion KRW | -21.29% |
| 2018 | 493.61 Billion KRW | 108.96% |
| 2017 | 236.22 Billion KRW | -0.59% |
| 2016 | 237.63 Billion KRW | -6.32% |
| 2015 | 253.66 Billion KRW | 7.11% |
| 2014 | 236.81 Billion KRW | 3.77% |
| 2013 | 228.21 Billion KRW | -7.95% |
| 2012 | 247.91 Billion KRW | -3.94% |
| 2011 | 258.08 Billion KRW | 2.56% |
| 2010 | 251.65 Billion KRW | 0.44% |
| 2009 | 250.54 Billion KRW | 8.67% |
| 2008 | 230.54 Billion KRW | 7.22% |
| 2007 | 215.01 Billion KRW | 43.84% |
| 2006 | 149.47 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 349.19 Billion KRW | -17.35% |
| 2024 Q1 | 422.51 Billion KRW | -1.52% |
| 2023 Q2 | 386.87 Billion KRW | 0.32% |
| 2023 FY | 442.46 Billion KRW | 10.36% |
| 2023 Q4 | 429.01 Billion KRW | 8.81% |
| 2023 Q1 | 385.63 Billion KRW | -3.81% |
| 2023 Q3 | 394.27 Billion KRW | 1.91% |
| 2022 Q3 | 397.79 Billion KRW | 3.12% |
| 2022 Q2 | 385.76 Billion KRW | -1.65% |
| 2022 Q1 | 392.23 Billion KRW | -1.3% |
| 2022 FY | 400.92 Billion KRW | 0.88% |
| 2022 Q4 | 400.92 Billion KRW | 0.79% |
| 2021 Q2 | 383.9 Billion KRW | -1.88% |
| 2021 FY | 397.41 Billion KRW | -0.89% |
| 2021 Q3 | 366 Billion KRW | -4.66% |
| 2021 Q4 | 397.41 Billion KRW | 8.58% |
| 2021 Q1 | 391.26 Billion KRW | -2.42% |
| 2020 FY | 400.96 Billion KRW | 3.2% |
| 2020 Q2 | 425.33 Billion KRW | 1.29% |
| 2020 Q3 | 405.22 Billion KRW | -4.73% |
| 2020 Q4 | 400.96 Billion KRW | -1.05% |
| 2020 Q1 | 419.93 Billion KRW | 8.08% |
| 2019 Q1 | 481.06 Billion KRW | -2.54% |
| 2019 Q4 | 388.53 Billion KRW | 2.53% |
| 2019 FY | 388.53 Billion KRW | -21.29% |
| 2019 Q2 | 401.98 Billion KRW | -16.44% |
| 2019 Q3 | 378.93 Billion KRW | -5.73% |
| 2018 Q1 | 233.89 Billion KRW | -0.99% |
| 2018 FY | 493.61 Billion KRW | 108.96% |
| 2018 Q4 | 493.61 Billion KRW | -7.04% |
| 2018 Q3 | 530.99 Billion KRW | 84.44% |
| 2018 Q2 | 287.88 Billion KRW | 23.08% |
| 2017 Q2 | 227.65 Billion KRW | 0.75% |
| 2017 Q1 | 225.95 Billion KRW | -4.91% |
| 2017 Q4 | 236.22 Billion KRW | -0.55% |
| 2017 FY | 236.22 Billion KRW | -0.59% |
| 2017 Q3 | 237.53 Billion KRW | 4.34% |
| 2016 Q4 | 237.63 Billion KRW | -2.4% |
| 2016 FY | 237.63 Billion KRW | -6.32% |
| 2016 Q1 | 266.68 Billion KRW | 5.13% |
| 2016 Q2 | 247.15 Billion KRW | -7.32% |
| 2016 Q3 | 243.47 Billion KRW | -1.49% |
| 2015 Q1 | 241.96 Billion KRW | 2.17% |
| 2015 FY | 253.66 Billion KRW | 7.11% |
| 2015 Q4 | 253.66 Billion KRW | 4.14% |
| 2015 Q3 | 243.58 Billion KRW | 4.96% |
| 2015 Q2 | 232.07 Billion KRW | -4.08% |
| 2014 Q4 | 236.81 Billion KRW | 1.64% |
| 2014 FY | 236.81 Billion KRW | 3.77% |
| 2014 Q2 | 227.99 Billion KRW | 0.0% |
| 2014 Q3 | 233 Billion KRW | 2.2% |
| 2013 Q4 | 228.21 Billion KRW | 0.0% |
| 2013 FY | 228.21 Billion KRW | -7.95% |
| 2013 Q1 | 252.47 Billion KRW | 1.84% |
| 2012 Q4 | 247.91 Billion KRW | -5.17% |
| 2012 Q1 | 259.82 Billion KRW | 0.0% |
| 2012 FY | 247.91 Billion KRW | -3.94% |
| 2012 Q2 | 256.8 Billion KRW | -1.16% |
| 2012 Q3 | 261.44 Billion KRW | 1.81% |
| 2011 FY | 258.08 Billion KRW | 2.56% |
| 2011 Q3 | 247.69 Billion KRW | 1.2% |
| 2011 Q1 | 251.65 Billion KRW | 0.96% |
| 2011 Q2 | 244.74 Billion KRW | -2.74% |
| 2010 Q3 | 250.69 Billion KRW | 3.37% |
| 2010 Q4 | 249.26 Billion KRW | -0.57% |
| 2010 Q2 | 242.52 Billion KRW | -3.2% |
| 2010 Q1 | 250.54 Billion KRW | 2.55% |
| 2010 FY | 251.65 Billion KRW | 0.44% |
| 2009 Q4 | 244.29 Billion KRW | 3.31% |
| 2009 Q3 | 236.47 Billion KRW | 2.85% |
| 2009 Q2 | 229.93 Billion KRW | 0.0% |
| 2009 FY | 250.54 Billion KRW | 8.67% |
| 2008 Q4 | 224.48 Billion KRW | 4.67% |
| 2008 Q2 | 193.11 Billion KRW | 0.0% |
| 2008 Q3 | 214.46 Billion KRW | 11.06% |
| 2008 FY | 230.54 Billion KRW | 7.22% |
| 2007 FY | 215.01 Billion KRW | 43.84% |
| 2007 Q2 | 153.28 Billion KRW | 0.0% |
| 2007 Q3 | 187.2 Billion KRW | 22.13% |
| 2007 Q4 | 201.72 Billion KRW | 7.76% |
| 2006 FY | 149.47 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -123.225% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 77.392% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 49.548% |
| HANDOK Inc. | 790.33 Billion KRW | 44.016% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -159.326% |
| Yuhan Corporation | 2814.07 Billion KRW | 84.277% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 66.358% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -373.328% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 77.333% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | -84.554% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 5.639% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -284.839% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | -87.049% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | -27.003% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -123.225% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | -5.552% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | 11.468% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | 24.93% |
| JW Holdings Corporation | 1176.26 Billion KRW | 62.384% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | 27.615% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 68.45% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 31.405% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -26.388% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -187.236% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | -19.365% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | 9.206% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -123.225% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 58.958% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 75.007% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 31.405% |
| Yuhan Corporation | 2814.07 Billion KRW | 84.277% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | 49.72% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -95.261% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 55.475% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 31.405% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | -5.373% |
| Korea United Pharm Inc. | 468.86 Billion KRW | 5.63% |
| CKD Bio Corp. | 293.78 Billion KRW | -50.607% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | 12.901% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | 21.684% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | -10.277% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -26.388% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 69.611% |
| Boryung Corporation | 922.36 Billion KRW | 52.029% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 5.639% |
| JW Lifescience Corporation | 255.83 Billion KRW | -72.947% |